Gapping up
In reaction to earnings/guidance:
- UMC +0.8% (August revs)
Other news:
- ECOM +54.4% (to be acquired for $23.10 per share)
- ISEE +42.3% (topline data from Zimura GATHER2 phase 3 clinical trial in geographic atrophy)
- GLUE +10% (receives FDA clearance of Investigational New Drug Application for MRT-2359)
- IDYA +4.9% (reports first-patient-in for Phase I clinical trial to evaluate darovasertib monotherapy)
- LPTX +4% (New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq at the ESMO Congress)
- ILMN +4% (confirms it intends to appeal European Commission's decision in GRAIL deal)
- MNKD +2.9% (completes phase 1 study of inhaled clofazimine)
- ATHA +2.8% (update to its plans for the ongoing LIFT-AD clinical trial of fosgonimeton)
- PAC +2.7% (August traffic)
- TKR +2.5% (to acquire GGB Bearing Technology, expanding its engineered bearing portfolio with complementary products)
- HUT +2.1% (production and operations update for August 2022)
- IRWD +1.3% (topline data from a Phase III clinical trial evaluating LINZESS 72 mcg)
- DVN +1.2% (Devon Energy and Delfin Midstream enter LNG Export Partnership)
- GOL +1% (August traffic)
Analyst comments:
- EURN +1.5% (upgraded to Buy from Hold at Jefferies)
- FRO +0.8% (upgraded to Buy from Hold at Jefferies)
